Literature DB >> 28637379

Neuropsychological outcomes of pediatric demyelinating diseases: a review.

Alexander Tan1,2, Cole Hague2, Benjamin M Greenberg1,3, Lana Harder1,4.   

Abstract

Immune-mediated central nervous system (CNS) demyelinating diseases impact various areas of the brain, optic nerves, and/or spinal cord and can result in a wide range of neurologic symptoms including adverse cognitive outcomes. Neuropsychological outcomes in adult multiple sclerosis (MS) are well documented, while literature on such outcomes in pediatric cohorts is more limited. Furthermore, literature on neuropsychological outcomes in pediatric acute disseminated encephalomyelitis (ADEM), neuromyelitis optica (NMO), and transverse myelitis (TM) is even more limited. This paper is the first to review what is known about neuropsychological outcomes associated with immune-mediated CNS demyelinating diseases, with a focus on pediatric MS, ADEM, NMO, and TM. Additionally, this review illuminates the need to clarify differences in neuropsychological sequelae between conditions, characterize longitudinal cognitive outcomes, and investigate neuropsychological outcomes in relation to clinical variables (e.g., age of onset, disease duration, number of relapses) and psychosocial variables (e.g., fatigue, emotional problems, behavioral functioning) to better understand neuropsychological outcomes associated with these conditions.

Entities:  

Keywords:  ADEM; Demyelinating; multiple sclerosis; neuropsychology; pediatric

Mesh:

Year:  2017        PMID: 28637379     DOI: 10.1080/09297049.2017.1339785

Source DB:  PubMed          Journal:  Child Neuropsychol        ISSN: 0929-7049            Impact factor:   2.500


  1 in total

1.  Pronounced Structural and Functional Damage in Early Adult Pediatric-Onset Multiple Sclerosis with No or Minimal Clinical Disability.

Authors:  Antonio Giorgio; Jian Zhang; Maria Laura Stromillo; Francesca Rossi; Marco Battaglini; Lucia Nichelli; Marzia Mortilla; Emilio Portaccio; Bahia Hakiki; Maria Pia Amato; Nicola De Stefano
Journal:  Front Neurol       Date:  2017-11-14       Impact factor: 4.003

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.